Company Description
Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson’s disease and related disorders.
Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson’s disease and gastrointestinal tract.
The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia.
Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.
| Country | United States |
| Founded | 2008 |
| IPO Date | Dec 23, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 9 |
| CEO | Milton Werner |
Contact Details
Address: 3350 Riverwood Parkway SE, Suite 1900 Atlanta, Georgia 30339 United States | |
| Phone | 678 392 3419 |
| Website | inhibikase.com |
Stock Details
| Ticker Symbol | IKT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $10.00 |
| CIK Code | 0001750149 |
| CUSIP Number | 45719W106 |
| ISIN Number | US45719W2052 |
| Employer ID | 26-3407249 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Charles Warren Olanow B.Sc., F.R.C.P.C., M.D. | Chief Executive Officer of Clintrex Research Corporation and Member of Scientific Advisory Board |
| Dr. Milton H. Werner Ph.D. | Chief Executive Officer, President and Director |
| Garth Lees-Rolfe CPA | Chief Financial Officer |
| Dr. Surendra Singh | Head of Chemistry, Manufacturing and Controls |
| Dan Williams | Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 18, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Nov 18, 2024 | DEF 14A | Other definitive proxy statements |
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | 10-Q | Quarterly Report |
| Nov 8, 2024 | PRE 14A | Other preliminary proxy statements |
| Oct 28, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Oct 28, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Oct 25, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Oct 22, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Oct 22, 2024 | 8-K | Current Report |